PACAP protects against salsolinol-induced toxicity in dopaminergic SH-SY5Y cells: Implication for Parkinson's disease

Dwayne Brown, A. Tamás, D. Reglodi, Yousef Tizabi

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) is an endogenous 38 amino acid containing neuropeptide with various cytoprotective functions including neuroprotection. Administration of PACAP has been shown to reduce damage induced by ischemia, trauma, or exogenous toxic substances. Moreover, mice deficient in PACAP are more vulnerable to damaging insults. In this study, we sought to determine whether PACAP may also be protective against salsolinol-induced toxicity in SH-SY5Y cells and, if so, elucidate its mechanism(s) of action. Salsolinol (SALS) is an endogenous dopamine metabolite with selective toxicity to nigral dopaminergic neurons, which are directly implicated in Parkinson's disease (PD). SH-SY5Y cells, derived from human neuroblastoma cells, express high levels of dopaminergic activity and are used extensively as a model to study these neurons. Exposure of SH-SY5Y cells to 400 μM SALS for 24 h resulted in approximately 50 % cell death that was mediated by apoptosis as determined by cell flow cytometry and increases in caspase-3 levels. Cellular toxicity was also associated with reductions in brain-derived neurotrophic factor and phosphorylated cyclic AMP response element-binding protein. Pretreatment with PACAP dose-dependently attenuated SALS-induced toxicity and the associated apoptosis and the chemical changes. PACAP receptor antagonist PACAP6-38, in turn, dose-dependently blocked the effects of PACAP. Neither PACAP nor PACAP antagonist had any effect of its own on cellular viability. These results suggest the protective effects of PACAP in a cellular model of PD. Hence, PACAP or its agonists could be of therapeutic benefit in PD.

Original languageEnglish
Pages (from-to)600-607
Number of pages8
JournalJournal of Molecular Neuroscience
Volume50
Issue number3
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Pituitary Adenylate Cyclase-Activating Polypeptide
Parkinson Disease
Pituitary Adenylate Cyclase-Activating Polypeptide Receptors
salsolinol
Apoptosis
Cyclic AMP Response Element-Binding Protein
Poisons
Dopaminergic Neurons
Brain-Derived Neurotrophic Factor
Substantia Nigra
Neuropeptides
Neuroblastoma
Caspase 3
Dopamine
Flow Cytometry
Cell Death
Ischemia

Keywords

  • Apoptosis
  • BDNF
  • Neuroprotection
  • p-CREB
  • PACAP
  • Salsolinol
  • SH-SY5Y cell line

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

PACAP protects against salsolinol-induced toxicity in dopaminergic SH-SY5Y cells : Implication for Parkinson's disease. / Brown, Dwayne; Tamás, A.; Reglodi, D.; Tizabi, Yousef.

In: Journal of Molecular Neuroscience, Vol. 50, No. 3, 07.2013, p. 600-607.

Research output: Contribution to journalArticle

@article{2422c13a26924bb9b44d70c6d8ccab93,
title = "PACAP protects against salsolinol-induced toxicity in dopaminergic SH-SY5Y cells: Implication for Parkinson's disease",
abstract = "Pituitary adenylate cyclase-activating polypeptide (PACAP) is an endogenous 38 amino acid containing neuropeptide with various cytoprotective functions including neuroprotection. Administration of PACAP has been shown to reduce damage induced by ischemia, trauma, or exogenous toxic substances. Moreover, mice deficient in PACAP are more vulnerable to damaging insults. In this study, we sought to determine whether PACAP may also be protective against salsolinol-induced toxicity in SH-SY5Y cells and, if so, elucidate its mechanism(s) of action. Salsolinol (SALS) is an endogenous dopamine metabolite with selective toxicity to nigral dopaminergic neurons, which are directly implicated in Parkinson's disease (PD). SH-SY5Y cells, derived from human neuroblastoma cells, express high levels of dopaminergic activity and are used extensively as a model to study these neurons. Exposure of SH-SY5Y cells to 400 μM SALS for 24 h resulted in approximately 50 {\%} cell death that was mediated by apoptosis as determined by cell flow cytometry and increases in caspase-3 levels. Cellular toxicity was also associated with reductions in brain-derived neurotrophic factor and phosphorylated cyclic AMP response element-binding protein. Pretreatment with PACAP dose-dependently attenuated SALS-induced toxicity and the associated apoptosis and the chemical changes. PACAP receptor antagonist PACAP6-38, in turn, dose-dependently blocked the effects of PACAP. Neither PACAP nor PACAP antagonist had any effect of its own on cellular viability. These results suggest the protective effects of PACAP in a cellular model of PD. Hence, PACAP or its agonists could be of therapeutic benefit in PD.",
keywords = "Apoptosis, BDNF, Neuroprotection, p-CREB, PACAP, Salsolinol, SH-SY5Y cell line",
author = "Dwayne Brown and A. Tam{\'a}s and D. Reglodi and Yousef Tizabi",
year = "2013",
month = "7",
doi = "10.1007/s12031-013-0015-7",
language = "English",
volume = "50",
pages = "600--607",
journal = "Journal of Molecular Neuroscience",
issn = "0895-8696",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - PACAP protects against salsolinol-induced toxicity in dopaminergic SH-SY5Y cells

T2 - Implication for Parkinson's disease

AU - Brown, Dwayne

AU - Tamás, A.

AU - Reglodi, D.

AU - Tizabi, Yousef

PY - 2013/7

Y1 - 2013/7

N2 - Pituitary adenylate cyclase-activating polypeptide (PACAP) is an endogenous 38 amino acid containing neuropeptide with various cytoprotective functions including neuroprotection. Administration of PACAP has been shown to reduce damage induced by ischemia, trauma, or exogenous toxic substances. Moreover, mice deficient in PACAP are more vulnerable to damaging insults. In this study, we sought to determine whether PACAP may also be protective against salsolinol-induced toxicity in SH-SY5Y cells and, if so, elucidate its mechanism(s) of action. Salsolinol (SALS) is an endogenous dopamine metabolite with selective toxicity to nigral dopaminergic neurons, which are directly implicated in Parkinson's disease (PD). SH-SY5Y cells, derived from human neuroblastoma cells, express high levels of dopaminergic activity and are used extensively as a model to study these neurons. Exposure of SH-SY5Y cells to 400 μM SALS for 24 h resulted in approximately 50 % cell death that was mediated by apoptosis as determined by cell flow cytometry and increases in caspase-3 levels. Cellular toxicity was also associated with reductions in brain-derived neurotrophic factor and phosphorylated cyclic AMP response element-binding protein. Pretreatment with PACAP dose-dependently attenuated SALS-induced toxicity and the associated apoptosis and the chemical changes. PACAP receptor antagonist PACAP6-38, in turn, dose-dependently blocked the effects of PACAP. Neither PACAP nor PACAP antagonist had any effect of its own on cellular viability. These results suggest the protective effects of PACAP in a cellular model of PD. Hence, PACAP or its agonists could be of therapeutic benefit in PD.

AB - Pituitary adenylate cyclase-activating polypeptide (PACAP) is an endogenous 38 amino acid containing neuropeptide with various cytoprotective functions including neuroprotection. Administration of PACAP has been shown to reduce damage induced by ischemia, trauma, or exogenous toxic substances. Moreover, mice deficient in PACAP are more vulnerable to damaging insults. In this study, we sought to determine whether PACAP may also be protective against salsolinol-induced toxicity in SH-SY5Y cells and, if so, elucidate its mechanism(s) of action. Salsolinol (SALS) is an endogenous dopamine metabolite with selective toxicity to nigral dopaminergic neurons, which are directly implicated in Parkinson's disease (PD). SH-SY5Y cells, derived from human neuroblastoma cells, express high levels of dopaminergic activity and are used extensively as a model to study these neurons. Exposure of SH-SY5Y cells to 400 μM SALS for 24 h resulted in approximately 50 % cell death that was mediated by apoptosis as determined by cell flow cytometry and increases in caspase-3 levels. Cellular toxicity was also associated with reductions in brain-derived neurotrophic factor and phosphorylated cyclic AMP response element-binding protein. Pretreatment with PACAP dose-dependently attenuated SALS-induced toxicity and the associated apoptosis and the chemical changes. PACAP receptor antagonist PACAP6-38, in turn, dose-dependently blocked the effects of PACAP. Neither PACAP nor PACAP antagonist had any effect of its own on cellular viability. These results suggest the protective effects of PACAP in a cellular model of PD. Hence, PACAP or its agonists could be of therapeutic benefit in PD.

KW - Apoptosis

KW - BDNF

KW - Neuroprotection

KW - p-CREB

KW - PACAP

KW - Salsolinol

KW - SH-SY5Y cell line

UR - http://www.scopus.com/inward/record.url?scp=84878930078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878930078&partnerID=8YFLogxK

U2 - 10.1007/s12031-013-0015-7

DO - 10.1007/s12031-013-0015-7

M3 - Article

C2 - 23625270

AN - SCOPUS:84878930078

VL - 50

SP - 600

EP - 607

JO - Journal of Molecular Neuroscience

JF - Journal of Molecular Neuroscience

SN - 0895-8696

IS - 3

ER -